Skip to main content

Cerebral Amyloid Angiopathy

3
Pipeline Programs
4
Companies
4
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Alnylam Pharmaceuticals
1 program
1
ALN-APPPhase 22 trials
Active Trials
NCT06393712Recruiting200Est. Dec 2029
NCT05231785Recruiting60Est. Apr 2029
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
Colchicine 0.5mgPhase 21 trial
Active Trials
NCT07026994Recruiting80Est. Dec 2027
Pfizer
PfizerNEW YORK, NY
1 program
1
PonezumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT01821118Completed36Est. Sep 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
UNION therapeuticsColchicine 0.5mg
Alnylam PharmaceuticalsALN-APP
PfizerPonezumab
Alnylam PharmaceuticalsALN-APP

Clinical Trials (4)

Total enrollment: 376 patients across 4 trials

NCT07026994UNION therapeuticsColchicine 0.5mg

Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage

Start: Jun 2025Est. completion: Dec 202780 patients
Phase 2Recruiting
NCT06393712Alnylam PharmaceuticalsALN-APP

A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

Start: May 2024Est. completion: Dec 2029200 patients
Phase 2Recruiting
NCT01821118PfizerPonezumab

Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy

Start: Jun 2013Est. completion: Sep 201536 patients
Phase 2Completed
NCT05231785Alnylam PharmaceuticalsALN-APP

A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

Start: Feb 2022Est. completion: Apr 202960 patients
Phase 1Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 376 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.